| Company Name: |
T&W GROUP |
| Tel: |
021-61551611 13296011611 |
| Email: |
contact@trustwe.com |
N6-Ethyl-2'-C-methyladenosine manufacturers
|
| | N6-Ethyl-2'-C-methyladenosine Basic information |
| Product Name: | N6-Ethyl-2'-C-methyladenosine | | Synonyms: | N6-Ethyl-2'-C-methyladenosine;Adenosine, N-ethyl-2'-C-methyl- (9CI);N6-Ethyl-2’-C-methyladenosine;(2R,3R,4R,5R)-2-(6-(ethylamino)-9H-purin-9-yl)-5-(hydroxymethyl)-3-methyltetrahydrofuran-3,4-diol | | CAS: | 714250-18-7 | | MF: | C13H19N5O4 | | MW: | 309.32 | | EINECS: | | | Product Categories: | | | Mol File: | 714250-18-7.mol |  |
| | N6-Ethyl-2'-C-methyladenosine Chemical Properties |
| Boiling point | 622.5±65.0 °C(Predicted) | | density | 1+-.0.1 g/cm3(Predicted) | | pka | 13.20±0.70(Predicted) |
| | N6-Ethyl-2'-C-methyladenosine Usage And Synthesis |
| Uses | N6-Ethyl-2’-C-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1]. | | References | [1] Man S, et al. Potential and promising anticancer drugs from adenosine and its analogs. Drug Discov Today. 2021 Jun;26(6):1490-1500. DOI:10.1016/j.drudis.2021.02.020
[2] Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. DOI:10.2174/138161212801227005 |
| | N6-Ethyl-2'-C-methyladenosine Preparation Products And Raw materials |
|